Opinion statement
Postoperative radiation therapy (RT), either alone or in combination with chemotherapy, is the mainstay of treatment for primary and/or metastatic brain tumors. The majority of patients with brain tumors will have significant symptoms of their disease and of RT that will have a negative impact on their quality of life and neurocognitive function. The symptoms of brain tumors depend on tumor location. Radiation-induced brain injury is a complex and dynamic process involving all cells in the brain, including endothelial and oligodendroglial cells, astrocytes, microglia, neurons, and neuronal stem cells. The symptoms of radiation-induced brain injury may be acute, subacute, or chronic, occurring hours, days, weeks, months, and even years after exposure to radiation, the pathogenesis of which is oxidative stress and inflammation. At present, there are no effective preventive approaches for radiation-induced brain injury. Rather, the management of radiation-induced fatigue, changes in mood, and cognitive dysfunction involves a multidisciplinary approach using pharmacologic, behavioral, and rehabilitative therapies. Given the prevalence of brain neoplasms and the high incidence of the radiation-induced symptom cluster and brain injury, clinical research to address these important clinical problems is critical.
Similar content being viewed by others
References and Recommended Reading
Shaw EG:Central nervous system overview. In Clinical Radiation Oncology. Edited by Gunderson LL, Tepper JE. Philadelphia:Churchill-Livingstone; 2000:314–335.
Gleason J, Case D, Rapp S, et al.:Symptom clusters in newly diagnosed brain tumor patients. Abstract presented at the 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA; June 2–6, 2006.
Saconn PA, Ip E, Rapp S, et al.:Symptom clusters in irradiated brain tumor survivors. Abstract presented at the 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA; June 2–6, 2006.
Dodd MJ, Miaskowski C, Lee KA:Occurrence of symptom clusters. J Natl Cancer Inst Monogr 2004, 32:76–78. This is the first article in the literature to define symptom clusters.
Dodd MJ, Miaskowski C, Paul SM:Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum 2001, 28:465–470.
Weitzner MA, Meyers CA, Valentine AD:Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 1995, 7:347–350. This is the first article in the literature describing the use of methylphenidate for brain tumor patients.
Mulhern RK, Khan RB, Kaplan S, et al.:Short-term efficacy of methylphenidate:a randomized, doubleblind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol 2004, 22:4795–4803.
Butler J, Case D, Atkins J, et al.:A phase III double blind placebo controlled prospective randomized clinical trial of effect of d-throe-methylphenidate HCL (d-MPH) on quality of life in brain tumor patients receiving radiation therapy [abstract]. Int J Radiat Oncol Biol Phys 2005, 63(Supp1):80.
Weitzner MA, Meyers CA, Gelke CK, et al.:The Functional Assessment of Cancer Therapy (FACT) scale:development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995, 75:1151–1161. This article validated the FACT-Br as the most commonly used quality-of-life instrument for brain tumor patients.
Yellen SB, Cella DF, Webster K, et al.:Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997, 13:63–67.
Halperin EC, Constine LS, Tarbell NJ, Kun LE:Pediatric Radiation Oncology, edn 2. New York:Raven Press; 1994.
Wen PY, Marks PW:Medical management of patients with brain tumors. Curr Opin Oncol 2002, 14:299–307.
Stupp R, Dietrich PY, Ostermann Kraljevic S, et al.:Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375–1382.
Forsyth PA, Kelly PJ, Casano TL, et al.:Radiation necrosis or glioma recurrence:is computer assisted stereotactic biopsy useful? J Neurosurg 1995, 82:436–444.
Liu CY, Yim BY, Wozniak AJ:Anticoagulation therapy for radiation-induced myelopathy. Ann Pharmacother 2001, 35:188–191.
Leber KA, Eder HG, Kovac H, et al.:Treatment of cerebral radionecrosis by hyperbaric oxygen therapy. Stereotact Funct Neurosurg 1998, 70(Suppl1):229–236.
Kim JH, Brown SL, Kolozsvary A, et al.:Modification of radiation injury by ramipril, inhibitor of the angiotensin-converting enzyme, on optic neuropathy in the rat. Radiat Res 2004, 161:137–142.
Laukkanen E, Klonof H, Allan B, et al.:The role of prophylactic brain irradiation in limited stage small-cell lung cancer:clinical, neuropsychologic, and CT sequelae. Int J Radiat Oncol Biol Phys 1988, 14:1109–1117.
Johnson BE, Becker B, Goff WB, et al.:Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. J Clin Oncol 1985, 3:1659–1667.
Halberg F, Kramer J, Moore I, et al.:Prophylactic cranial irradiation dose effects on late cognitive function in children treated for acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 1991, 11:13–16.
DeAngelis LM, Delattre J, Posner JB:Radiation-induced dementia in patients cured of metastases. Neurology 1989, 39:789–796.
Frytak S, Shaw JN, O'Neill BP, et al.:Leuko-encephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol 1989, 12:27–33.
Silber J, Radcliffe J, Peckham V, et al.:Whole-brain irradiation and decline in intelligence:the influence of dose and age on IQ score. J Clin Oncol 1992, 10:1390–1396.
Ris M, Noll R:Long-term neurobehavioral outcome in pediatric brain-tumor patients:review and methodological critique. J Clin Exp Neuropsychol 1994, 16:21–42.
Mulhern R, Hancock J, Fairclough D, Kun L:Neuropsychological status of children treated for brain tumors:a critical review and integrative analysis. Med Pediat Oncol 1992, 20:181–191.
Mulhern R, Fairclough D, Ochs D:A prospective comparison of neuropsychological performance of children surviving leukemia who received 18Gy, 24Gy, or no cranial irradiation. J Clin Oncol 1991, 9:1348–1356.
Ochs J, Mulhern R, Fairclough D, et al.:Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate:a prospective study. J Clin Oncol 1991, 9:145–151.
Shaw EG, Rosdhal R, D'Agostino RB Jr, et al.:A phase II study of donepezil in irradiated brain tumor patients:effect on cognitive function, mood, and quality of life. J Clin Oncol 2006, 24:1415–1420. This is the first published report of a neurotherapeutic agent in long-term survivors of brain tumor irradiation.
McNair DM, Lorr M, Droppleman LF:Profile of Mood States Manual. San Diego:Educational and Industrial Testing Service; 1992.
Reitan RM:Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958, 8:271–276.
Wechsler D:Wechsler Adult Intelligence Scale-Revised Manual. New York:Psychological Corporation; 1981.
Fastenau PS, Denburg NL, Hufford BJ:Adult norms for the Rey-Osterrieth Complex Figure Test and for supplemental recognition and matching trials from the Extended Complex Figure Test. Clin Neuropsychol 1999, 13:30–47.
Kaplan EF, Goodglass H, Weintraub S:The Boston Naming Test. Boston:E Kaplan & H Goodglass; 1978.
Benton AL, Hamsher K:Multilingual Aphasia Examination. Iowa City:AJA Associates; 1983.
Delis DC, Kramer JH, Kaplan E, Ober BA:California Verbal Learning Test-Research Edition. New York:The Psychological Corp.; 1987.
Bryson HM, Benfield P:Donepezil. Drugs Aging 1997, 10:234–243.
Rogers SL, Doody RS, Mohs RC, Friedhoff LT ; the Donepezil Study Group:Donepezil improves cognition and global function in Alzheimer's disease. Arch Int Med 1998, 158:1021–1031.
Rogers SL, Farlow MR, Doody RS, et al.:The Donepezil Study Group:a 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998, 50:136–145.
Le Bars PL, Katz MM, Berman N, et al.:A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia. JAMA 1997, 278:1327–1332.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Butler, J.M., Rapp, S.R. & Shaw, E.G. Managing the cognitive effects of brain tumor radiation therapy. Curr. Treat. Options in Oncol. 7, 517–523 (2006). https://doi.org/10.1007/s11864-006-0026-5
Issue Date:
DOI: https://doi.org/10.1007/s11864-006-0026-5